Cannabis Europa London returns on 26-27 May 2026, bringing together operators, investors, clinicians and policymakers from across the global cannabis industry for two days of main stage debate, exhibition, and networking. This article is part of a series published by Business of Cannabis ahead of the event, drawing on the perspectives of Cannabis Europa’s leading sponsors and speakers, the figures setting the commercial, clinical, and regulatory agenda for cannabis in Europe and beyond.
Linnea is one of Switzerland’s longest-running and most respected manufacturers of premium botanical active ingredients for the pharmaceutical, nutraceutical, and cosmetic industries. Operating from a GMP-certified facility, the company is also a leader in medical cannabinoids, applying a pharma-driven approach to cannabinoid development. Ahead of the event, Business of Cannabis took the opportunity to pick the brains of Scientific Affairs Manager, Nora Rossini, about the future of pharmaceutical cannabinoids.
26–27 May 2026 · Barbican, London Cannabis Europa Two days of policy, capital and clinical strategy at the Barbican — convening operators, investors, regulators and clinicians from across the European cannabis market.
Get Your Ticket Now →
“It looks like Europe is entering a much more mature phase of development. The conversation is shifting from ‘whether’ cannabis will be accepted to ‘how’ sustainable, compliant and medically credible markets are built.
“Three developments stand out in particular. First, we are seeing continued growth in medical cannabis access across Europe, but with much higher expectations around product quality, consistency and clinical reliability. Regulators, physicians and patients increasingly expect cannabis products to meet pharmaceutical standards rather than consumer wellness expectations.
“Second, there is a clear movement toward regulation and GMP-driven supply chains. Companies that can demonstrate pharmaceutical manufacturing standards, validated processes and robust documentation are becoming structurally advantaged. This is especially important as cross-border trade within Europe continues to expand.
Nora Rossini, Scientific Affairs Manager, Linnea
“Third, the industry is becoming more evidence-driven and focused on education and clear guidelines (on dosages and indications). Healthcare professionals are demanding stronger clinical data, more precise formulations, predictable delivery systems, education and clear guidelines (on dosages and indications) and reliable outcomes. The companies that will succeed long term are those capable of combining botanical expertise with pharmaceutical discipline.
“At the same time, there is still fragmentation between national frameworks, which creates operational complexity. Europe remains a multi-market environment rather than a single unified market, and navigating those differences remains one of the industry’s defining challenges.”
“Many operators can produce cannabis extracts, but far fewer can consistently manufacture pharmaceutical-grade ingredients with the level of reproducibility expected in regulated healthcare environments. Physicians and regulators need products with clearly defined cannabinoid profiles, impurity controls, stability data and batch-to-batch consistency.
“Furthermore, Europe increasingly requires ingredients and finished products supported by validated processes, regulatory documentation and robust quality systems. This goes beyond cultivation; it requires deep expertise in extraction science, analytical methods and pharmaceutical manufacturing.
“There is also a gap between market enthusiasm and clinical integration. To expand physician confidence, the industry needs dosage precision, reliable delivery and more clinical evidence supporting specific therapeutic applications.”
“One important lesson from Switzerland is that, in general, the value of a pragmatic regulation combined with high-quality expectations, maintaining rigorous standards around manufacturing and product quality.”
The post Voices of Cannabis Europa: Nora Rossini, Scientific Affairs Manager, Linnea appeared first on Business of Cannabis.
Continue reading...
Linnea is one of Switzerland’s longest-running and most respected manufacturers of premium botanical active ingredients for the pharmaceutical, nutraceutical, and cosmetic industries. Operating from a GMP-certified facility, the company is also a leader in medical cannabinoids, applying a pharma-driven approach to cannabinoid development. Ahead of the event, Business of Cannabis took the opportunity to pick the brains of Scientific Affairs Manager, Nora Rossini, about the future of pharmaceutical cannabinoids.
26–27 May 2026 · Barbican, London Cannabis Europa Two days of policy, capital and clinical strategy at the Barbican — convening operators, investors, regulators and clinicians from across the European cannabis market.
Get Your Ticket Now →
As we head into Cannabis Europa, what do you see as the most significant developments shaping the European cannabis industry right now?
“It looks like Europe is entering a much more mature phase of development. The conversation is shifting from ‘whether’ cannabis will be accepted to ‘how’ sustainable, compliant and medically credible markets are built.
“Three developments stand out in particular. First, we are seeing continued growth in medical cannabis access across Europe, but with much higher expectations around product quality, consistency and clinical reliability. Regulators, physicians and patients increasingly expect cannabis products to meet pharmaceutical standards rather than consumer wellness expectations.
“Second, there is a clear movement toward regulation and GMP-driven supply chains. Companies that can demonstrate pharmaceutical manufacturing standards, validated processes and robust documentation are becoming structurally advantaged. This is especially important as cross-border trade within Europe continues to expand.
Nora Rossini, Scientific Affairs Manager, Linnea
“Third, the industry is becoming more evidence-driven and focused on education and clear guidelines (on dosages and indications). Healthcare professionals are demanding stronger clinical data, more precise formulations, predictable delivery systems, education and clear guidelines (on dosages and indications) and reliable outcomes. The companies that will succeed long term are those capable of combining botanical expertise with pharmaceutical discipline.
“At the same time, there is still fragmentation between national frameworks, which creates operational complexity. Europe remains a multi-market environment rather than a single unified market, and navigating those differences remains one of the industry’s defining challenges.”
READ MORE…
Voices of Cannabis Europa: Nora Rossini, Scientific Affairs Manager, Linnea
Voices of Cannabis Europa: Rebecca Allen Tapp, Product Manager, Paralab Green
Voices of Cannabis Europa: Adriano Fernandes Head of Growth and Business Development at CANNA
As European markets increasingly push towards pharmaceutical-grade formats, where do you see the greatest gap between current market supply and what is actually needed?
“Many operators can produce cannabis extracts, but far fewer can consistently manufacture pharmaceutical-grade ingredients with the level of reproducibility expected in regulated healthcare environments. Physicians and regulators need products with clearly defined cannabinoid profiles, impurity controls, stability data and batch-to-batch consistency.
“Furthermore, Europe increasingly requires ingredients and finished products supported by validated processes, regulatory documentation and robust quality systems. This goes beyond cultivation; it requires deep expertise in extraction science, analytical methods and pharmaceutical manufacturing.
“There is also a gap between market enthusiasm and clinical integration. To expand physician confidence, the industry needs dosage precision, reliable delivery and more clinical evidence supporting specific therapeutic applications.”
Switzerland has often been ahead of the curve on medical cannabis frameworks. What lessons from the Swiss experience do you think the rest of Europe has yet to absorb?
“One important lesson from Switzerland is that, in general, the value of a pragmatic regulation combined with high-quality expectations, maintaining rigorous standards around manufacturing and product quality.”
The post Voices of Cannabis Europa: Nora Rossini, Scientific Affairs Manager, Linnea appeared first on Business of Cannabis.
Continue reading...
